REGN Stock Recent News
REGN LATEST HEADLINES
On Friday, Regeneron Pharmaceuticals Inc. REGN reported upbeat second-quarter earnings.
The healthcare industry has been a remarkable place for investors to build significant portfolio returns through the years. Companies that are providing life-saving medicines, devices, and other products are often at the forefront of innovation in the healthcare space, a durable industry that tends to be broadly resilient even in times of economic unrest.
Regeneron Pharmaceuticals delivered strong Q2 results, driven by Dupixent and Libtayo growth that were enough to offset the decline of the Eylea franchise. The existing product portfolio and upcoming approvals should be more than sufficient to keep Regeneron in growth mode. The obesity pipeline expansion adds a new growth avenue for the company in the 2030s.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO George D.
Nonfarm Payrolls Come in SIgnificantly Below Expectations.
REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, this time in relation to observations from the regulator's inspection at a third-party manufacturing site.